The accumulation of aggregated amyloid-β (Aβ) in the brain is the first critical step in the pathogenesis of Alzheimer’s disease (AD), which also includes synaptic impairment, neuroinflammation, neuronal loss, and eventual cognitive defects. Emerging evidence suggests that impairment of Aβ phagocytosis and clearance is a common phenotype in late-onset AD. Rutin (quercetin-3-rutinoside) has long been investigated as a natural flavonoid with different biological functions in some pathological circumstances. Sodium rutin (NaR), could promote Aβ clearance by increasing microglial by increasing the expression levels of phagocytosis-related receptors in microglia. Moreover, NaR promotes a metabolic switch from anaerobic glycolysis to mitochondrial OXPHOS (oxidative phosphorylation), which could provide microglia with sufficient energy (ATP) for Aβ clearance. Thus, NaR administration could attenuate neuroinflammation and enhance mitochondrial OXPHOS and microglia-mediated Aβ clearance, ameliorating synaptic plasticity impairment and eventually reversing spatial learning and memory deficits. Our findings suggest that NaR is a potential therapeutic agent for AD.
A precise and selective reversed phase high-performance liquid chromatographic method was developed for quantifying huperzine A (HupA) in samples of the Huperziaceae in China. This method was used to quantify the levels of HupA in samples of Huperzia serrata collected from a single population at different times of the year, in different organs of the same H. serrata plant, and from different geographical locations of H. serrata plants in China. For different species of Huperziaceae, the highest content of HupA was found in Phlegmariurus carinatus. Members of the genus Phlegmariurus possessed higher levels of HupA than Huperzia species. H. serrata plants growing in humid forests contained significantly more HupA than plants growing in less humid environments. Finally, HupA content varied significantly by season, with the highest levels being found in mid fall and the lowest levels in early spring, suggesting that HupA is turned over in the plant.
Highlights d Use of CMap identified the phytochemical hyperforin as an anti-obesity agent in mice d Hyperforin promotes adipose tissue thermogenesis to promote weight loss d Dlat was identified and validated as a direct molecular target of hyperforin d Hyperforin-induced thermogenesis is modulated by a Dlat-AMPK-PGC1a axis
In recent decades,
bismuth telluride (Bi2Te3) has been in widespread
use for normal-temperature thermoelectric cooling. However, commercial
zone-melted bismuth telluride faces the big challenge of dramatically
decreased thermoelectric properties at higher temperature, which limits
its usage at intermediate temperature. In this contribution, the thermoelectric
performance of p-type bismuth telluride is enhanced via a synergistic
optimization by hot deformation and copper doping. Hot deformation
treatment boosts the grain growth and exhibits donor-like effects,
leading to improved electronic transport properties. Meanwhile, high-density
dislocations and lattice distortions induced by dynamic recrystallization
aggravate the phonon-related scattering and significantly compress
the lattice thermal conductivity. In addition, copper doping effectively
tunes the hole concentration, and the generated point defects also
reduce the lattice thermal conductivity. Consequently, a high ZT
max of 1.1 at 400 K and ZT
ave of 1.0 between 300–500 K were obtained in hot-deformed
Cu0.01Bi0.48Sb1.52Te3.
This study suggests that the synergistic effect of hot deformation
and copper doping is promising to boost the near-normal-temperature
thermoelectric power generation of Bi2Te3-based
thermoelectrics.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.